Pharsight

Epaned patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9808442 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US10154987 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US11040023 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US9669008 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US10772868 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US10786482 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US10039745 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US11173141 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US11141405 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

Epaned is owned by Azurity.

Epaned contains Enalapril Maleate.

Epaned has a total of 9 drug patents out of which 0 drug patents have expired.

Epaned was authorised for market use on 20 September, 2016.

Epaned is available in solution;oral dosage forms.

Epaned can be used as treatment of heart failure, treatment of hypertension.

The generics of Epaned are possible to be released after 25 March, 2036.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ENALAPRIL MALEATE ingredient

Market Authorisation Date: 20 September, 2016

Treatment: Treatment of hypertension; Treatment of heart failure

Dosage: SOLUTION;ORAL

How can I launch a generic of EPANED before it's drug patent expiration?
More Information on Dosage

EPANED family patents

Family Patents